Findings

What do systematic reviews say?

14 questions · 14 findings · 6 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 28.6%GRADE not reported 0 · 0%Very low 4 · 28.6%Low 5 · 35.7%Moderate 1 · 7.1%High 0 · 0%

Summary of findings table for metformin plus intensive diet and exercise vs intensive diet and exercise

Serious adverse events · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Diet vs physical activity or standard treatment

Serious adverse events · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 530 participants
Very low

Physical activity vs usual care

Serious adverse events · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 397 participants
Very low

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

SAEs · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 250 participants
Low

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Low

Summary of findings: pioglitazone monotherapy vs placebo

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
3 [0.32, 28.22]
2 studies · 187 participants
Very low

Summary of findings: pioglitazone monotherapy vs no intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
RR 0.71 [0.38, 1.32]
7 studies · 1211 participants
Low

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acarbose vs no intervention

Serious adverse events · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acarbose vs placebo

Serious adverse events · people at increased risk for developing type 2 diabetes

Acarbose showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in… 2018 · Cochrane Headline outcomes only
RR 1.12 [0.97, 1.29]
2 studies · 6625 participants
Low

Intervention not reported

Serious adverse events · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2312 participants
Low

Intervention not reported

Serious adverse events · people at risk for development of T2DM

1 finding from 1 review

Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 179 participants
Very low

Intervention not reported

Serious adverse events · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate

Intervention not reported

Serious adverse events · people at risk for the development of type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found